ScripLong non-coding RNA (lncRNA) is an emerging therapeutic modality that may offer actionable novel targets in a variety of disease settings, and Eli Lilly and Company , already a leader in obesity and
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AzurRx Will Take First Wave Name After